Category Archives: TB

Subsequent HPTN 052 data shows early HIV treatment is even more beneficial to patient, cost-effective

By on .

The good news keeps getting better for the HIV Prevention Trials Network (HPTN) 052 study, which found last year that HIV-infected persons on antiretroviral therapy (ART) were 96 percent less likely to transmit the virus to an uninfected partner through vaginal sex. At the International AIDS Conference (IAC) in Washington this week, two late-breaker sessions […]

New combo TB regimen proves potent and effective in Phase-II trials

By on .

Combination testing paradigm would reduce novel regimen testing time from decades to years

Early clinical trial results are promising for a new combination tuberculosis (TB) drug therapy that is proving potent and could reduce treatment time to just four months for patients with drug-sensitive TB as well as many drug-resistant strains…

TB response requires momentum of AIDS activism

By on .

Treatment Action Group’s leader Mark Harrington did not mince words Saturday at a consultation meeting on HIV and tuberculosis (TB) co-infection preceding the 2012 International AIDS Conference in Washington. Promoting TAG’s collaborative effort calling for “Zero TB Deaths, Zero New Infections, Zero Discrimination and Stigma,” Harrington was an invited panelist asked to discuss progress and […]

“Asleep at the Wheel:” The early response to the twin epidemics TB-HIV

By on .

We often cite the fact that tuberculosis (TB) fueled the spread of HIV in southern Africa, said Diane Havlir, MD, of the University of California at San Francisco and co-Chair of the 2012 International AIDS Conference (IAC). But AIDS also shaped the enormous spread of TB seen in southern Africa during the late 80s and […]

Report: GeneXpert TB diagnostics take off in low-resource countries

By on .

As of the end of the first quarter of 2012, nearly 864,000 GeneXpert MTB/RIF rapid tuberculosis (TB) diagnostic cartridges had been procured under manufacturer Cephied’s concessional pricing mechanism. The information was part of a the three-page report released in May by the Stop TB Department of the World Health Organization (WHO), giving an update on […]

UNITAID seeks innovative HIV, TB and malaria proposals

By on .

UNITAID is inviting letters of intent (LOI), or short conceptual presentations of a proposed project, on the topic of improving access to key preventive, diagnostic and treatment commodities for HIV, tuberculosis (TB) and malaria through market-based approaches.  UNITAID works to negotiate low pricing for diagnostics and medication for AIDS, tuberculosis and malaria in developing countries […]

PDPs agree to jointly develop new TB vaccine candidate

By on .

Aeras and the Infectious Disease Research Institute (IDRI) – two non-profit product development partnerships (PDPs) – announced Wednesday they will be joining together to develop IDRI’s novel tuberculosis (TB) vaccine candidate ID93/GLA-SE. The compound contains an IDRI-designed recombinant fusion-protein antigen (a protein substance foreign to the body that stimulates the immune system’s production of antibodies […]

PEPFAR releases report to Congress, an update on drug-resistant TB in India, and more…

By on .

The following “What We’re Reading” selection is a collection of articles, commentary and resources making headlines recently in global health news. PEPFAR releases 8th annual report to Congress: The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) program delivered its 8th annual report to Congress recently. The five-page document outlines the program’s progress as of […]

UN: World will fall short of ambitious 2015 HIV/AIDS goals

By on .

The United Nations (UN) General Assembly gave some bad news Monday – the 2015 global HIV/AIDS targets will not be met unless there is significant scale up in several areas. The targets were set by the 2011 Political Declaration on HIV and AIDS: Intensifying our Efforts to Eliminate HIV and AIDS. The declaration was adopted […]

U.S. is world’s largest funder of global health research and development

By on .

Report shows investments save lives and dollars

The U.S. government invested $12.7 billion over the past decade in the creation of new vaccines, drugs, diagnostics and other products for neglected diseases in the developing world. That’s according to a new report released by the Global Health Technologies Coalition (GHTC) and Policy Cures on Friday.

Of the 45 new products registered in that time to address these neglected diseases that affect more than 1 billion people around the world, the U.S. was involved in the development of 24 of them (or 52 percent).